Free Antimicrobial Screening of Compound Libraries
CO-ADD reaches out to chemists in academia and research organisations around the globe who have compounds ‘sitting on shelves’ that were not designed as antibiotics and would not otherwise be screened for antimicrobial activity. We are based at The University of Queensland's Institute for Molecular Bioscience in Brisbane, Australia.
CO-ADD is equipped to conduct screening campaigns against microorganisms and has access to a wide range of state-of-the-art equipment for high-throughput assays. Compounds are screened at no cost against a key panel of susceptible and drug-resistant bacterial, and fungal pathogens. So far we have screened over 300,000 compounds from 45 countries.
We ask for 1mg (or 100uL at 10 mg/mL) of pure compound which will be used for primary screening, hit confirmation, and if active will be used for a broader antimicrobial screening, cytotoxicity and a check for its purity.
We require all compounds to be soluble in DMSO and to be shipped as dry material in appropriate containers, such as 1-2 mL Eppendorf tubes. For larger collections we can arrange plates or tube-racks.
Step 1: Primary Screening
In the primary screening we test compound libraries against key ESKAPE pathogens, E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans. The screen will be at a single concentration (32 µg/mL) and will provide initial activity data to select compounds for further more detailed screening.
Step 2: Hit Confirmation
Active compounds from the primary screening will be tested in dose response antimicrobial assays to confirm their activity. Active compounds will be screened for adverse effects, such as cytotoxicity and haemolytic activity.
This is a free service and we make no claims on results or IP. The data will then be made available in an open access database for use by the community following a confidentiality period allowing you to publish or patent your positive hits. We also reserve the right to change the screening workflow as per demand and limit the free screening based on available resources.
Step 3: Hit Validation
The next step of the CO-ADD process would be to test the hit against a broader panel of microbes with multidrug-resistant (MDR) and pan-resistant bacterial strains and clinical isolates, with different co-factors (such as serum or lung surfactant). The Hit validation might also include initial ADMET screening, including microsome and plasma stability and protein binding, evaluating the basic drug qualities of the actives. This stage of the screening will be done only in collaboration (collaborative research agreement) with the research group, as additional material might be required, and additional structural analogues could be included to evaluate any structure-activity relationship.
> By sending compounds to CO-ADD, you agree to our terms and conditions.